Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 275

1.

Bayesian estimation of a semiparametric recurrent event model with applications to the penetrance estimation of multiple primary cancers in Li-Fraumeni syndrome.

Shin SJ, Li J, Ning J, Bojadzieva J, Strong LC, Wang W.

Biostatistics. 2018 Nov 14. doi: 10.1093/biostatistics/kxy066. [Epub ahead of print]

PMID:
30445420
2.

Long-term sequelae in survivors of childhood leukemia with Down syndrome: A childhood cancer survivor study report.

Goldsby RE, Stratton KL, Raber S, Ablin A, Strong LC, Oeffinger K, Sklar CA, Armstrong GT, Robison LL, Bhatia S, Leisenring WM.

Cancer. 2018 Feb 1;124(3):617-625. doi: 10.1002/cncr.31065. Epub 2017 Nov 3.

PMID:
29105081
3.

Genome-Wide Association Study to Identify Susceptibility Loci That Modify Radiation-Related Risk for Breast Cancer After Childhood Cancer.

Morton LM, Sampson JN, Armstrong GT, Chen TH, Hudson MM, Karlins E, Dagnall CL, Li SA, Wilson CL, Srivastava DK, Liu W, Kang G, Oeffinger KC, Henderson TO, Moskowitz CS, Gibson TM, Merino DM, Wong JR, Hammond S, Neglia JP, Turcotte LM, Miller J, Bowen L, Wheeler WA, Leisenring WM, Whitton JA, Burdette L, Chung C, Hicks BD, Jones K, Machiela MJ, Vogt A, Wang Z, Yeager M, Neale G, Lear M, Strong LC, Yasui Y, Stovall M, Weathers RE, Smith SA, Howell R, Davies SM, Radloff GA, Onel K, Berrington de González A, Inskip PD, Rajaraman P, Fraumeni JF Jr, Bhatia S, Chanock SJ, Tucker MA, Robison LL.

J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx058.

4.

Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic.

Bojadzieva J, Amini B, Day SF, Jackson TL, Thomas PS, Willis BJ, Throckmorton WR, Daw NC, Bevers TB, Strong LC.

Fam Cancer. 2018 Apr;17(2):287-294. doi: 10.1007/s10689-017-0034-6.

PMID:
28988289
5.

Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.

Zhou R, Xu A, Gingold J, Strong LC, Zhao R, Lee DF.

Trends Pharmacol Sci. 2017 Oct;38(10):908-927. doi: 10.1016/j.tips.2017.07.004. Epub 2017 Aug 14. Review.

6.

Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis.

Ballinger ML, Best A, Mai PL, Khincha PP, Loud JT, Peters JA, Achatz MI, Chojniak R, Balieiro da Costa A, Santiago KM, Garber J, O'Neill AF, Eeles RA, Evans DG, Bleiker E, Sonke GS, Ruijs M, Loo C, Schiffman J, Naumer A, Kohlmann W, Strong LC, Bojadzieva J, Malkin D, Rednam SP, Stoffel EM, Koeppe E, Weitzel JN, Slavin TP, Nehoray B, Robson M, Walsh M, Manelli L, Villani A, Thomas DM, Savage SA.

JAMA Oncol. 2017 Dec 1;3(12):1634-1639. doi: 10.1001/jamaoncol.2017.1968.

7.

Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome.

Kratz CP, Achatz MI, Brugières L, Frebourg T, Garber JE, Greer MC, Hansford JR, Janeway KA, Kohlmann WK, McGee R, Mullighan CG, Onel K, Pajtler KW, Pfister SM, Savage SA, Schiffman JD, Schneider KA, Strong LC, Evans DGR, Wasserman JD, Villani A, Malkin D.

Clin Cancer Res. 2017 Jun 1;23(11):e38-e45. doi: 10.1158/1078-0432.CCR-17-0408. Review.

8.

Recommendations for Surveillance for Children with Leukemia-Predisposing Conditions.

Porter CC, Druley TE, Erez A, Kuiper RP, Onel K, Schiffman JD, Wolfe Schneider K, Scollon SR, Scott HS, Strong LC, Walsh MF, Nichols KE.

Clin Cancer Res. 2017 Jun 1;23(11):e14-e22. doi: 10.1158/1078-0432.CCR-17-0428. Review.

9.

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.

Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi T.

Cancer Res. 2017 Mar 15;77(6):1250-1260. doi: 10.1158/0008-5472.CAN-16-2179. Review.

10.

Estimating TP53 Mutation Carrier Probability in Families with Li-Fraumeni Syndrome Using LFSPRO.

Peng G, Bojadzieva J, Ballinger ML, Li J, Blackford AL, Mai PL, Savage SA, Thomas DM, Strong LC, Wang W.

Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):837-844. doi: 10.1158/1055-9965.EPI-16-0695. Epub 2017 Jan 30.

11.

CANCER. The cancer predisposition revolution.

Malkin D, Garber JE, Strong LC, Friend SH.

Science. 2016 May 27;352(6289):1052-3. doi: 10.1126/science.aag0832. No abstract available.

PMID:
27230363
12.

Breast Cancer Risk in Childhood Cancer Survivors Without a History of Chest Radiotherapy: A Report From the Childhood Cancer Survivor Study.

Henderson TO, Moskowitz CS, Chou JF, Bradbury AR, Neglia JP, Dang CT, Onel K, Novetsky Friedman D, Bhatia S, Strong LC, Stovall M, Kenney LB, Barnea D, Lorenzi E, Hammond S, Leisenring WM, Robison LL, Armstrong GT, Diller LR, Oeffinger KC.

J Clin Oncol. 2016 Mar 20;34(9):910-8. doi: 10.1200/JCO.2015.62.3314. Epub 2015 Dec 23.

13.

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC Jr, Bennett JM, Benz EJ Jr, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ Jr, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA.

Mayo Clin Proc. 2015 Aug;90(8):996-1000. doi: 10.1016/j.mayocp.2015.06.001. Epub 2015 Jul 23. No abstract available.

14.

Characterization of genomic alterations in radiation-associated breast cancer among childhood cancer survivors, using comparative genomic hybridization (CGH) arrays.

Yang XR, Killian JK, Hammond S, Burke LS, Bennett H, Wang Y, Davis SR, Strong LC, Neglia J, Stovall M, Weathers RE, Robison LL, Bhatia S, Mabuchi K, Inskip PD, Meltzer P.

PLoS One. 2015 Mar 12;10(3):e0116078. doi: 10.1371/journal.pone.0116078. eCollection 2015.

15.

A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus.

Cozen W, Timofeeva MN, Li D, Diepstra A, Hazelett D, Delahaye-Sourdeix M, Edlund CK, Franke L, Rostgaard K, Van Den Berg DJ, Cortessis VK, Smedby KE, Glaser SL, Westra HJ, Robison LL, Mack TM, Ghesquieres H, Hwang AE, Nieters A, de Sanjose S, Lightfoot T, Becker N, Maynadie M, Foretova L, Roman E, Benavente Y, Rand KA, Nathwani BN, Glimelius B, Staines A, Boffetta P, Link BK, Kiemeney L, Ansell SM, Bhatia S, Strong LC, Galan P, Vatten L, Habermann TM, Duell EJ, Lake A, Veenstra RN, Visser L, Liu Y, Urayama KY, Montgomery D, Gaborieau V, Weiss LM, Byrnes G, Lathrop M, Cocco P, Best T, Skol AD, Adami HO, Melbye M, Cerhan JR, Gallagher A, Taylor GM, Slager SL, Brennan P, Coetzee GA, Conti DV, Onel K, Jarrett RF, Hjalgrim H, van den Berg A, McKay JD.

Nat Commun. 2014 Jun 12;5:3856. doi: 10.1038/ncomms4856.

16.

Long-term risk of medical conditions associated with breast cancer treatment.

Hill DA, Horick NK, Isaacs C, Domchek SM, Tomlinson GE, Lowery JT, Kinney AY, Berg JS, Edwards KL, Moorman PG, Plon SE, Strong LC, Ziogas A, Griffin CA, Kasten CH, Finkelstein DM.

Breast Cancer Res Treat. 2014 May;145(1):233-43. doi: 10.1007/s10549-014-2928-4. Epub 2014 Apr 3.

17.

Telomere content and risk of second malignant neoplasm in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.

Gramatges MM, Liu Q, Yasui Y, Okcu MF, Neglia JP, Strong LC, Armstrong GT, Robison LL, Bhatia S.

Clin Cancer Res. 2014 Feb 15;20(4):904-11. doi: 10.1158/1078-0432.CCR-13-2076. Epub 2013 Nov 25.

18.

Increased oxidative metabolism in the Li-Fraumeni syndrome.

Wang PY, Ma W, Park JY, Celi FS, Arena R, Choi JW, Ali QA, Tripodi DJ, Zhuang J, Lago CU, Strong LC, Talagala SL, Balaban RS, Kang JG, Hwang PM.

N Engl J Med. 2013 Mar 14;368(11):1027-32. doi: 10.1056/NEJMoa1214091.

19.

Identification of TP53 as an acute lymphocytic leukemia susceptibility gene through exome sequencing.

Powell BC, Jiang L, Muzny DM, Treviño LR, Dreyer ZE, Strong LC, Wheeler DA, Gibbs RA, Plon SE.

Pediatr Blood Cancer. 2013 Jun;60(6):E1-3. doi: 10.1002/pbc.24417. Epub 2012 Dec 19.

20.

Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium.

Mai PL, Malkin D, Garber JE, Schiffman JD, Weitzel JN, Strong LC, Wyss O, Locke L, Means V, Achatz MI, Hainaut P, Frebourg T, Evans DG, Bleiker E, Patenaude A, Schneider K, Wilfond B, Peters JA, Hwang PM, Ford J, Tabori U, Ognjanovic S, Dennis PA, Wentzensen IM, Greene MH, Fraumeni JF Jr, Savage SA.

Cancer Genet. 2012 Oct;205(10):479-87. doi: 10.1016/j.cancergen.2012.06.008. Epub 2012 Aug 29.

21.

A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32.

Cozen W, Li D, Best T, Van Den Berg DJ, Gourraud PA, Cortessis VK, Skol AD, Mack TM, Glaser SL, Weiss LM, Nathwani BN, Bhatia S, Schumacher FR, Edlund CK, Hwang AE, Slager SL, Fredericksen ZS, Strong LC, Habermann TM, Link BK, Cerhan JR, Robison LL, Conti DV, Onel K.

Blood. 2012 Jan 12;119(2):469-75. doi: 10.1182/blood-2011-03-343921. Epub 2011 Nov 15.

22.

Activating mutation in MET oncogene in familial colorectal cancer.

Neklason DW, Done MW, Sargent NR, Schwartz AG, Anton-Culver H, Griffin CA, Ahnen DJ, Schildkraut JM, Tomlinson GE, Strong LC, Miller AR, Stopfer JE, Burt RW.

BMC Cancer. 2011 Oct 4;11:424. doi: 10.1186/1471-2407-11-424.

23.

Evaluation of polymorphisms in EWSR1 and risk of Ewing sarcoma: a report from the Childhood Cancer Survivor Study.

DuBois SG, Goldsby R, Segal M, Woo J, Copren K, Kane JP, Pullinger CR, Matthay KK, Witte J, Lessnick SL, Robison LL, Bhatia S, Strong LC.

Pediatr Blood Cancer. 2012 Jul 15;59(1):52-6. doi: 10.1002/pbc.23263. Epub 2011 Jul 25.

24.

Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma.

Best T, Li D, Skol AD, Kirchhoff T, Jackson SA, Yasui Y, Bhatia S, Strong LC, Domchek SM, Nathanson KL, Olopade OI, Huang RS, Mack TM, Conti DV, Offit K, Cozen W, Robison LL, Onel K.

Nat Med. 2011 Jul 24;17(8):941-3. doi: 10.1038/nm.2407.

25.

Early onset HER2-positive breast cancer is associated with germline TP53 mutations.

Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM, Litton JK, Olopade OI, Hortobagyi GN, Strong LC, Arun BK.

Cancer. 2012 Feb 15;118(4):908-13. doi: 10.1002/cncr.26377. Epub 2011 Jul 14. Erratum in: Cancer. 2012 May 1;118(9):2561.

26.

Clinically relevant changes in family history of cancer over time.

Ziogas A, Horick NK, Kinney AY, Lowery JT, Domchek SM, Isaacs C, Griffin CA, Moorman PG, Edwards KL, Hill DA, Berg JS, Tomlinson GE, Anton-Culver H, Strong LC, Kasten CH, Finkelstein DM, Plon SE.

JAMA. 2011 Jul 13;306(2):172-8. doi: 10.1001/jama.2011.955.

27.

Sex-specific effect of the TP53 PIN3 polymorphism on cancer risk in a cohort study of TP53 germline mutation carriers.

Fang S, Krahe R, Bachinski LL, Zhang B, Amos CI, Strong LC.

Hum Genet. 2011 Dec;130(6):789-94. doi: 10.1007/s00439-011-1039-0. Epub 2011 Jun 19.

PMID:
21688173
28.

Identification of genetic susceptibility to childhood cancer through analysis of genes in parallel.

Plon SE, Wheeler DA, Strong LC, Tomlinson GE, Pirics M, Meng Q, Cheung HC, Begin PR, Muzny DM, Lewis L, Biegel JA, Gibbs RA.

Cancer Genet. 2011 Jan;204(1):19-25. doi: 10.1016/j.cancergencyto.2010.11.001. Erratum in: Cancer Genet. 2011 May;204(5):284.

29.

Joint effects of germ-line TP53 mutation, MDM2 SNP309, and gender on cancer risk in family studies of Li-Fraumeni syndrome.

Wu CC, Krahe R, Lozano G, Zhang B, Wilson CD, Jo EJ, Amos CI, Shete S, Strong LC.

Hum Genet. 2011 Jun;129(6):663-73. doi: 10.1007/s00439-011-0957-1. Epub 2011 Feb 9.

30.

Wt1 ablation and Igf2 upregulation in mice result in Wilms tumors with elevated ERK1/2 phosphorylation.

Hu Q, Gao F, Tian W, Ruteshouser EC, Wang Y, Lazar A, Stewart J, Strong LC, Behringer RR, Huff V.

J Clin Invest. 2011 Jan;121(1):174-83. doi: 10.1172/JCI43772. Epub 2010 Dec 1.

31.

Myelodysplastic syndromes arising in patients with germline TP53 mutation and Li-Fraumeni syndrome.

Talwalkar SS, Yin CC, Naeem RC, Hicks MJ, Strong LC, Abruzzo LV.

Arch Pathol Lab Med. 2010 Jul;134(7):1010-5. doi: 10.1043/2009-0015-OA.1.

PMID:
20586629
32.

Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations.

Fang S, Krahe R, Lozano G, Han Y, Chen W, Post SM, Zhang B, Wilson CD, Bachinski LL, Strong LC, Amos CI.

PLoS One. 2010 May 26;5(5):e10813. doi: 10.1371/journal.pone.0010813.

33.

Effects of measured susceptibility genes on cancer risk in family studies.

Wu CC, Strong LC, Shete S.

Hum Genet. 2010 Mar;127(3):349-57. doi: 10.1007/s00439-009-0774-y. Epub 2009 Dec 29.

34.

The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research.

Robison LL, Armstrong GT, Boice JD, Chow EJ, Davies SM, Donaldson SS, Green DM, Hammond S, Meadows AT, Mertens AC, Mulvihill JJ, Nathan PC, Neglia JP, Packer RJ, Rajaraman P, Sklar CA, Stovall M, Strong LC, Yasui Y, Zeltzer LK.

J Clin Oncol. 2009 May 10;27(14):2308-18. doi: 10.1200/JCO.2009.22.3339. Epub 2009 Apr 13. Review.

35.

Common familial colorectal cancer linked to chromosome 7q31: a genome-wide analysis.

Neklason DW, Kerber RA, Nilson DB, Anton-Culver H, Schwartz AG, Griffin CA, Lowery JT, Schildkraut JM, Evans JP, Tomlinson GE, Strong LC, Miller AR, Stopfer JE, Finkelstein DM, Nadkarni PM, Kasten CH, Mineau GP, Burt RW.

Cancer Res. 2008 Nov 1;68(21):8993-7. doi: 10.1158/0008-5472.CAN-08-1376.

36.

Psychological functioning in persons considering genetic counseling and testing for Li-Fraumeni syndrome.

Peterson SK, Pentz RD, Marani SK, Ward PA, Blanco AM, LaRue D, Vogel K, Solomon T, Strong LC.

Psychooncology. 2008 Aug;17(8):783-9. doi: 10.1002/pon.1352.

PMID:
18688785
37.

An information-theoretic analysis of genetics, gender and age in cancer patients.

Atwal GS, Rabadán R, Lozano G, Strong LC, Ruijs MW, Schmidt MK, van't Veer LJ, Nevanlinna H, Tommiska J, Aittomäki K, Bougeard G, Frebourg T, Levine AJ, Bond GL.

PLoS One. 2008 Apr 9;3(4):e1951. doi: 10.1371/journal.pone.0001951.

38.

Validity of models for predicting BRCA1 and BRCA2 mutations.

Parmigiani G, Chen S, Iversen ES Jr, Friebel TM, Finkelstein DM, Anton-Culver H, Ziogas A, Weber BL, Eisen A, Malone KE, Daling JR, Hsu L, Ostrander EA, Peterson LE, Schildkraut JM, Isaacs C, Corio C, Leondaridis L, Tomlinson G, Amos CI, Strong LC, Berry DA, Weitzel JN, Sand S, Dutson D, Kerber R, Peshkin BN, Euhus DM.

Ann Intern Med. 2007 Oct 2;147(7):441-50.

39.

Secondary sarcomas in childhood cancer survivors: a report from the Childhood Cancer Survivor Study.

Henderson TO, Whitton J, Stovall M, Mertens AC, Mitby P, Friedman D, Strong LC, Hammond S, Neglia JP, Meadows AT, Robison L, Diller L.

J Natl Cancer Inst. 2007 Feb 21;99(4):300-8.

PMID:
17312307
40.

Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome.

Wu CC, Shete S, Amos CI, Strong LC.

Cancer Res. 2006 Aug 15;66(16):8287-92.

41.

Evaluation of a decision aid for families considering p53 genetic counseling and testing.

Peterson SK, Pentz RD, Blanco AM, Ward PA, Watts BG, Marani SK, James LC, Strong LC.

Genet Med. 2006 Apr;8(4):226-33.

42.

Characterization of BRCA1 and BRCA2 mutations in a large United States sample.

Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A, Peterson LE, Schildkraut JM, Isaacs C, Peshkin BN, Corio C, Leondaridis L, Tomlinson G, Dutson D, Kerber R, Amos CI, Strong LC, Berry DA, Euhus DM, Parmigiani G.

J Clin Oncol. 2006 Feb 20;24(6):863-71.

43.

Assessing BRCA carrier probabilities in extended families.

Barcenas CH, Hosain GM, Arun B, Zong J, Zhou X, Chen J, Cortada JM, Mills GB, Tomlinson GE, Miller AR, Strong LC, Amos CI.

J Clin Oncol. 2006 Jan 20;24(3):354-60.

PMID:
16421416
44.

Generation or birth cohort effect on cancer risk in Li-Fraumeni syndrome.

Brown BW, Costello TJ, Hwang SJ, Strong LC.

Hum Genet. 2005 Dec;118(3-4):489-98. Epub 2005 Nov 12.

PMID:
16284780
45.

Long-term outcomes of adult survivors of childhood cancer.

Robison LL, Green DM, Hudson M, Meadows AT, Mertens AC, Packer RJ, Sklar CA, Strong LC, Yasui Y, Zeltzer LK.

Cancer. 2005 Dec 1;104(11 Suppl):2557-64.

46.

Increased risk of cancer among siblings of long-term childhood cancer survivors: a report from the childhood cancer survivor study.

Friedman DL, Kadan-Lottick NS, Whitton J, Mertens AC, Yasui Y, Liu Y, Meadows AT, Robison LL, Strong LC.

Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1922-7.

47.

The risk of cancer in twins: a report from the childhood cancer survivor study.

Kadan-Lottick NS, Kawashima T, Tomlinson G, Friedman DL, Yasui Y, Mertens AC, Robison LL, Strong LC.

Pediatr Blood Cancer. 2006 Apr;46(4):476-81.

PMID:
16078231
48.

Global detection of molecular changes reveals concurrent alteration of several biological pathways in nonsmall cell lung cancer cells.

Ju Z, Kapoor M, Newton K, Cheon K, Ramaswamy A, Lotan R, Strong LC, Koo JS.

Mol Genet Genomics. 2005 Sep;274(2):141-54. Epub 2005 Oct 11.

49.

Genetic mapping of a third Li-Fraumeni syndrome predisposition locus to human chromosome 1q23.

Bachinski LL, Olufemi SE, Zhou X, Wu CC, Yip L, Shete S, Lozano G, Amos CI, Strong LC, Krahe R.

Cancer Res. 2005 Jan 15;65(2):427-31.

50.

Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.

Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G.

Cell. 2004 Dec 17;119(6):861-72.

Supplemental Content

Loading ...
Support Center